Infectious Diseases
Conditions
Interventions
Case series:Nil
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The evaluation of rationality will include three components: the necessity of empiric therapy, the necessity and appropriateness of targeted therapy, and the identification of the aspects (such as frequency, dosage, and combination) to be optimized. Specific judgment criteria are as follows: 1. Necessity: matching any of the following the three scenarios: (1) Severe infections: The patients met any of the following criteria: 1) At least one of hypotension, hypoxemia and altered state of consciousness and the condition(s) are caused by bacterial infection; 2) Sepsis qSOFA score (including respiratory rate, blood pressure and state of consciousness) is no less than 2; 3) For ertapenem, the severity has met the severe infection for specific type of infections defined by well-recognized international or Chinese guidelines including acute cholangitis and cholecystitis (Tokyo Guidelines 2018), community-acquired pneumoniae (Chinese Medical Association Guidelines 2016), and intra-abdominal infections ((Chinese Medical Association Guidelines 2019); (2) Non-severe infections but no other drugs are available: Drugs selected should be in the antibacterial drug list in the hospital and meet their medical indications; no other drugs are available is defined to meet both criteria: 1) The pathogens are resistant to all beta-lactams but carbapenems (excluding ceftazidime-avibactam); 2) The pathogens are also resistant to non-ß-lactams except colistin, tigecycline and those that are usually not used alone such as amikacin. (3) Febrile neutropenia; 2. Appropriateness: matching any of the following the two scenarios: (1) In vitro susceptibility of the pathogens exhibits susceptible to carbapenems (severe infections,febrile neutropenia, non-severe infections but no other drugs are available); (2) As an agent in the combined therapy for carbapenem-resistant Enterobacteriaceae; 3. Aspects and opportunities to be optimized: matching both of the following scenarios: (1) Dosage and frequency according to the drug instructions or the national guidance; (2) There is no unnecessary combination of drugs, such as the combination of nitroimidazoles to cover anaerobes.
Exclusion criteria
Exclusion criteria: No
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical symptoms;susceptibility tests;dosage;frequency; | — |
Countries
China
Contacts
Public ContactZhiyong Zong
West China Hospital, Sichuan University
Outcome results
None listed